Functional Comparison of Innate Immune Signaling Pathways in Primates by Barreiro, Luis B. et al.
Functional Comparison of Innate Immune Signaling
Pathways in Primates
Luis B. Barreiro





1Department of Human Genetics, University of Chicago, Chicago, Illinois, United States of America, 2Department of Statistics, University of Chicago, Chicago, Illinois,
United States of America
Abstract
Humans respond differently than other primates to a large number of infections. Differences in susceptibility to infectious
agents between humans and other primates are probably due to inter-species differences in immune response to infection.
Consistent with that notion, genes involved in immunity-related processes are strongly enriched among recent targets of
positive selection in primates, suggesting that immune responses evolve rapidly, yet providing only indirect evidence for
possible inter-species functional differences. To directly compare immune responses among primates, we stimulated
primary monocytes from humans, chimpanzees, and rhesus macaques with lipopolysaccharide (LPS) and studied the
ensuing time-course regulatory responses. We find that, while the universal Toll-like receptor response is mostly conserved
across primates, the regulatory response associated with viral infections is often lineage-specific, probably reflecting rapid
host–virus mutual adaptation cycles. Additionally, human-specific immune responses are enriched for genes involved in
apoptosis, as well as for genes associated with cancer and with susceptibility to infectious diseases or immune-related
disorders. Finally, we find that chimpanzee-specific immune signaling pathways are enriched for HIV–interacting genes. Put
together, our observations lend strong support to the notion that lineage-specific immune responses may help explain
known inter-species differences in susceptibility to infectious diseases.
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Introduction
Due to our natural focus on humans, we know of a large
number of diseases or medical conditions that affect humans more
severely than non-human primates. Examples include progression
to AIDS following infection with HIV, progression to malaria
following infection with Plasmodium falciparum, Alzheimer’s disease,
cancer, and adverse complications following infection with
hepatitis B and C (reviewed in [1,2]). Differences in susceptibility
to infectious agents between humans and other primates might be
explained, at least in part, by inter-species differences in immune
response to infection. Indeed, a large body of work indicates that
immune systems are rapidly evolving. In particular, while very
little comparative functional data in primates has been collected,
recent genomic scans for signatures of natural selection have
reported that genes involved in immunity processes are strongly
enriched among targets of positive section in human and
chimpanzee [3–11].
Immune responses are typically classified as either ‘innate’ or
‘adaptive.’ Historically, the focus of most immunological studies
has been on the adaptive response and its hallmarks, namely the
generation of a large repertoire of antigen-recognizing receptors
and immunological memory. Recently, however, more effort has
been expended on understanding the innate immune system, as it
became clear that innate immunity is an evolutionarily ancient
defense mechanism, which governs the initial detection of
pathogens and stimulates the first line of host defense [12–15].
Moreover, innate immune responses were shown to play a pivotal
role in the development of pathogen-specific humoral and cellular
adaptive immune responses, which are mediated by B and T cells
[16–18].
The recognition of pathogens by the innate immune system is
primarily mediated by phagocytic cells (e.g., monocytes, macro-
phages, and dendritic cells) through germline-encoded receptors,
known as pattern recognition receptors (PRRs) [17,19,20]. The
PRRs recognize conserved molecular features characteristic of the
microbial world, commonly referred to as pathogen-associated
molecular patterns (PAMPs) [17,19,20]. Among the different
PRRs, the Toll-like receptor (TLR) family, which comprises 10
functional members in humans, has been the most extensively
studied. For example, by stimulating primary cell cultures with
different TLR agonists in vitro (e.g., references [21–23]) and by
studying mouse models that lack one or several TLRs (e.g.,
references [24–26]), it has been shown that TLRs can be activated
in response to virtually any microbe that invades the host.
Once activated, TLRs play a crucial role in orchestrating the
response to pathogenic microbial infections through the induction
of two major regulatory programs. First, a universal regulatory
response, which can be activated by all TLRs and is triggered by
infection with a diverse range of microbes or TLR agonists
PLoS Genetics | www.plosgenetics.org 1 December 2010 | Volume 6 | Issue 12 | e1001249[21,22,27–29]. This response has been interpreted as a generic
‘alarm signal’ for infection [22,28,29]. Second, individual TLRs
can activate regulatory programs that are specific to individual
microbial agents [19]. Comparative functional studies of TLR-
mediated immune response in primates might therefore shed light
on inter-species differences in susceptibility to certain infectious
agents. However, at present, there is very little functional data with
which one can study the evolution of the immune system in
primates.
Results
In order to study functional differences between the innate
immune response of humans and two close evolutionary relatives,
chimpanzees (Pan troglodytes) and rhesus macaques (Macaca mulatta),
we stimulated primary monocytes from six individuals from each
of the three species with LPS for 4, 12, and 24 hours (see Figure S1
for an illustration of the study design). LPS activates the TLR
pathway (specifically, TLR4) and mimics an infection with Gram
negative bacteria [16–18]. We chose this treatment because LPS,
via TLR4, activates multiple immune signaling pathways, leading
to the induction of both inflammatory and ‘viral-like’ responses
[19]. Additionally, the stimulation of immune cells with LPS was
shown to result in a very similar regulatory response (87% overlap)
to the response to infection with a live bacteria such as E. coli [22].
To confirm that the LPS treatment activated TLR4-mediated
immune responses, we used quantitative PCR to estimate the
induction levels of three inflammatory cytokines (IL6, IL1b, and
TNF). In all samples (from all individuals at all time points), levels
of the three inflammatory cytokines were significantly higher
following stimulation with LPS (Figure S2). However, we noticed
that the quantitative responses to the treatment in the chimpanzee
samples were lower than those of the human and rhesus macaque
samples. This observation probably reflects a technical difficulty in
culturing chimpanzee primary monocytes without inducing a
general stress response, which results in the attenuation of the
quantitative response to further stimuli (see Materials and Methods
for more details). In what follows, we therefore focus primarily on
qualitative rather than quantitative differences between individuals
and species in the regulatory response to stimulation with LPS.
LPS-mediated immune responses in primates
To estimate and compare gene expression levels in samples
from multiple species, we used a multispecies microarray, which
includes orthologous probes from human, chimpanzee, and rhesus
macaque for 18,109 genes [30]. Following processing and
normalization of the array data, we used a gene-specific linear
mixed-effect model (see Materials and Methods) to identify inter-
species differences in the regulatory response to stimulation with
LPS (the ‘treatment’). To minimize the number of falsely identified
differences across species, we applied two statistical cutoffs for
classifying genes as responding to the treatment. Specifically,
conditional on observing a treatment effect with high statistical
confidence in one species, we assumed that a treatment effect likely
occurred in other species as well, and relaxed the statistical cutoff
for the classification of such secondary observations (see Materials
and Methods for more details and the specific statistical cutoffs
used). This procedure minimizes the number of falsely identified
inter-species differences that might ultimately arise from incom-
plete power to identify differences in gene expression levels
following the treatment.
Using this approach, we identified 3,170 genes whose
expression levels changed following the treatment in at least one
species, at any time point, of which 793 genes responded in all
three species (Figure 1A, Table S1, Figure S3). As expected, genes
that responded to stimulation with LPS in all three species are
enriched with genes involved in immune-related biological
processes such as ‘‘inflammatory-response’’ and ‘‘cytokine-signal-
ing’’, as well as in specific immune-related pathways including the
Toll-like receptor pathway, cytokine-cytokine receptor interac-
tions, and the Jak-STAT signaling pathway (FDR for all reported
results is ,0.01; Figure 1B, 1C, Table S2). Consistent with
previous observations in functional studies of the immune system
in mice [21,27], we found that the conserved regulatory response
to stimulation with LPS in primates included an enrichment of
genes that are likely regulated by the transcription factor NF-kB
(P,10
25) and several interferon regulatory factors (e.g., IRF7 and
IRF1; P,10
23; Figure 1D, Table S3). Put together, these
observations clearly demonstrate that the monocytes from all
three species responded to the treatment with LPS by engaging
TLR4-mediated regulatory pathways [19], leading to the
induction of pro-inflammatory and anti-viral immune responses
via the activation of NF-kB and IRF mediated pathways.
To gain further insight into the evolution of LPS-induced
immune responses in primates, we classified genes as participating
in either the universal regulatory response to infection (which can
be triggered by a diverse range of microbes or TLR stimuli
[21,22,27]), or in the microbial-specific response (which we then
further classified as responses to either bacterial or viral infections
[21,22,27]). Based on these classifications (Table S4), we examined
how genes falling into each of the categories responded to infection
in humans, chimpanzees, and rhesus macaques. We found that the
majority (58%) of genes involved in universal response to infection
showed a conserved regulatory response to stimulation with LPS in
all three species, compared to only 31% of genes known to
respond primarily to either viral or bacterial infection (x
2 test,
P,0.001; Figure 2A). Viewed from a different perspective, we
observed that the proportion of genes involved in immune
response to viral infections is significantly higher (1.5-fold) among
genes that responded to stimulation with LPS in only one of the
species, compared with genes that responded to the treatment in
Author Summary
We know of a large number of diseases or medical
conditions that affect humans more severely than non-
human primates, such as AIDS, malaria, hepatitis B, and
cancer. These differences likely arise from different
immune responses to infection among species. However,
due to the lack of comparative functional data across
species, it remains unclear how the immune system of
humans and other primates differ. In this work, we present
the first genome-wide characterization of functional
differences in innate immune responses between humans
and our closest evolutionary relatives. Our results indicate
that ‘‘core’’ immune responses, those that are critical to
fight any invading pathogen, are the most conserved
across primates and that much of the divergence in
immune responses is observed in genes that are involved
in response to specific microbial and viral agents. In
addition, we show that human-specific immune responses
are enriched for genes involved in apoptosis and cancer
biology, as well as with genes previously associated with
susceptibility to infectious diseases or immune-related
disorders. Finally, we find that chimpanzee-specific im-
mune signaling pathways are enriched for HIV–interacting
genes. Our observations may therefore help explain
known inter-species differences in susceptibility to infec-
tious diseases.
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2 test, P=0.002; Figure 2B). Taken together, our
data strongly support the notion that the universal TLR response
is mostly conserved across primates and that much of the
divergence in immune response is observed in genes that are
involved in response to specific microbial and viral agents.
Characterization of species-specific innate immune
responses
We proceeded by focusing on species-specific immune respons-
es. Using the conservative approach described above, we identified
335, 273, and 393 genes as responding to stimulation with LPS
exclusively in the human, chimpanzee, and rhesus macaque
monocytes, respectively (see Figure 3A–3C for examples). To
characterize these gene sets, we considered functional annotations
based on the GO and KEGG databases (Table S5, S6, S7).
Somewhat surprisingly, the only significant enrichments (after
correction for multiple tests) were observed among the 335 genes
that responded to the treatment exclusively in humans. We found
that human-specific immune response was enriched for genes in
pathways previously associated with cancer (e.g., Chronic myeloid
leukemia or prostate cancer; P#3.0610
23, FDR,0.06), the B cell
receptor signaling pathway (P=3.2610
23, FDR=0.06), and
pathways related to apoptosis (P=5.0610
23, FDR=0.07; see
Table S5 for a complete list of significant results). Further, by using
the STRING database [31] to visualize all known functional
interactions between these 335 genes, we found that 151 of the
genes in this set (45%) are known to interact with each other –
using the default cutoff suggested by STRING to define a
functional interaction (Table S8). Applying a more stringent cutoff
(a STRING confidence-score higher than 0.7), we identified 78
genes (23%) that interact with each other, in a functional module
that is enriched with genes involved in cancer biology and
apoptosis pathways (Figure 4, Table S9). In order to obtain further
support for interactions across these 78 genes, we used GRAIL, a
tool that uses text mining of PubMed abstracts to identify
published functional interactions between genes. We found that
43 out of the 78 human-specific immune response genes (55%) had
a GRAIL score of P-text,0.05, statistically supporting the notion
that they have a functional interaction with at least one other gene
in the list (only ,7% of genes are expected to have GRAIL score
of P-text,0.05 in randomly chosen sets of 78 genes).
We then considered networks of co-expressed genes (namely
genes with coordinated patterns of expression) for each species, to
find additional putative modules of interacting genes (see Materials
and Methods). We found 33, 17 and 32 regulatory modules in
humans, chimpanzees and rhesus macaques, respectively, with an
average connectivity (|r|) higher than 0.5 (Figure 5, Table S10,
S11, S12). Based on 100 random permutations of the gene
expression values, we estimated that the number of clusters with
|r|.0.5 expected by chance alone is 1.2861.04, 1.1661.08, or
1.3761.08, using data from humans, chimpanzees and rhesus
macaques, respectively, suggesting that the observed excess
of regulatory modules likely describe meaningful biological
relationships.
Figure 1. LPS-mediated innate immune response to infection in humans, chimpanzees, and rhesus macaques. (A) Venn-diagram
showing the number of genes whose expression levels were altered following stimulation with LPS in humans, chimpanzees and rhesus macaques at
any time point (see Figure S4 for data from specific time points). (B) Gene ontology (GO) enrichment analysis using the subset of genes that
responded to the treatment in all three species. GO terms related to immunity processes are plotted (see Table S2 for results including all GO terms).
(C) KEGG pathway enrichment analysis for genes that responded to the treatment in all three species. (D) Transcription factor binding site enrichment
analysis in the promoters of genes that responded to the treatment in all three species (see Table S3 for complete results).
doi:10.1371/journal.pgen.1001249.g001
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which are significantly enriched for several biological processes
involved in extracellular matrix remodeling (P,0.002; Table S10).
The second largest regulatory module is significantly enriched for
genes involved in apoptotic pathways (P,0.04; Table S10).
Interestingly, ‘‘apoptosis-related’’ processes appeared to also be
enriched among genes in one of the largest regulatory modules
identified in chimpanzees, with 23 genes (Table S11), as well as
among three large regulatory modules (.30 genes each) identified
in rhesus macaques (Table S12). As the regulatory modules
comprise of mutually exclusive sets of genes across the three
species (by the nature of the analysis), these observations support
the notion that immunological-associated apoptosis mechanisms
evolve rapidly in primates.
Finally, we asked whether the observed inter-species differences
in immune response might provide insight into the mechanisms
underlying differences in susceptibility to infectious diseases
between humans and non-human primates. To do so, we
considered the subsets of genes that responded to stimulation
with LPS exclusively in humans, chimpanzees or rhesus macaques,
and examined whether they were enriched for genes previously
reported to be associated with immune disorders in humans and/
or susceptibility to infectious diseases (see Materials and Methods).
We found an enrichment of ‘‘immune-related-disease-genes’’
among genes that responded to the treatment with LPS exclusively
in humans (x
2 test, P=0.03; Figure 6A). Interestingly, we also
found that the set of genes that responded to stimulation with LPS
exclusively in chimpanzees was enriched with genes that code for
host cell proteins known to interact with HIV-1 (Figure 6B; x
2 test,
P=0.0002). No significant enrichment of HIV-1 interacting genes
was observed among genes that responded to stimulation with LPS
exclusively in either humans or rhesus macaques. This observation
is robust with respect to the specific cutoffs used to classify
genes that responded to stimulation in LPS in only one species
(Figure S5).
Discussion
We have performed a genome-wide study of LPS-mediated
immune responses in primary monocytes from humans, chimpan-
zees, and rhesus macaques. Our study design allowed us to
characterize conserved innate immune response mechanisms in
primates as well as to identify species-specific regulatory responses
to stimulation with LPS.
An important difficulty of all studies of gene regulation in
primary tissues from primates, apes in particular, is the inability to
stage the environment for each of the donor individuals across
species. In our study, biological replication within species partially
addresses this difficulty, but the possibility that a subset of the
observed inter-species differences in gene regulation are due to
differences in environments (e.g., diet) across species still exists. An
additional difficulty is that most available tools for manipulating
cell cultures and performing immune-related assays have not been
optimized to work with non-human primate cells. We addressed
this issue by performing a large number of quality controls,
including the validation of the response to stimulation with LPS in
each cell culture by using qPCR. Nevertheless, our observation of
systematic differences in the quantitative response to infection
across cultures from different species (in particular, from
chimpanzees) probably has a technical rather than a biological
explanation. For that reason, we chose to draw conclusions
primarily based on qualitative differences between species. Thus,
the inter-species regulatory differences reported in our study likely
Figure 2. Universal TLR response is more conserved than the
immune responses to specific bacterial or viral infections. (A)
The proportion of genes that responded to the treatment in all three
species, in any two species, or in only one species are plotted for the
subsets of genes classified as part of the universal TLR response, the
immune responses specific to bacterial infections, or the immune
responses specific to viral infections (B) The proportion of genes
classified as part of the universal TLR response, the immune responses
specific to bacterial infections, or the immune responses specific to viral
infections among genes that responded to the treatment in all three
species or exclusively in one species. Genes were classified as part of the
universal, bacterial, or viral TLR response, based on the findings of Amid
and colleagues [21].
doi:10.1371/journal.pgen.1001249.g002
Figure 3. Species-specific responses to infection. Examples of (A)
human-specific, (B) chimpanzee-specific, and (C) rhesus-specific im-
mune responses to the treatment. In all panels, the log2 fold difference
in expression levels (+SE) following the treatment (y-axis) is plotted for
each species at the different time points following infection (x-axis).
doi:10.1371/journal.pgen.1001249.g003
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immune response between humans, chimpanzees and rhesus
macaques.
Conserved innate-immune responses in primates
We identified 793 genes that responded to stimulation with LPS
in all three species. As expected, this set of genes was significantly
enriched for genes involved in immune responses, and specifically
for genes involved in TLR-mediated pathways. Some examples of
conserved TLR4-induced immune responses include the strong
up-regulation of several pro-inflammatory cytokines, such as IL-6,
IL1-b and tumor necrosis factor (TNF), and chemokines, such as
CCL2, CCL3 and CCL4, whose roles are to recruit other effector
cells to the inflammatory site [29,32]. We also observed a
conserved up-regulation of the anti-inflammatory cytokine IL-10,
probably to control the levels of inflammatory response and avoid
tissue damage [29], as well as the up-regulation of several
interferon-a inducible genes (e.g., IFIH1, IFIT1, and IFIT3).
Overall, conserved immune responses were enriched for genes
whose expression levels are regulated by the transcription factor
NF-kB, or by several interferon regulatory factors, which are the
master regulators of TLR4-dependent pathways. Interestingly,
before infection, the expression levels of many of these master
regulators (e.g., REL, NFKB1, RELB, IRF2, IRF9) were different
across the three species, while post-infection, their expression
converged to practically the same level, regardless of species
(Figure S6). This observation suggests that the regulatory response
of these key transcription factors likely evolve under strong
evolutionary constraints, probably to ensure efficient downstream
immune responses.
A known property of the regulatory programs mediated by
different TLRs is the activation of both a universal response
(shared by all TLRs) as well as a response that is specific to each
microbial agent (or TLR ligand) [21,22,27–29]. We found that the
universal TLR response is remarkably more conserved across
primates compared to microbial-specific responses. From an
evolutionary perspective this observation makes intuitive sense.
Indeed, ‘core’ immune responses, which are critical to fight any
invading pathogen, are expected to be under stronger evolutionary
constraint compared to immune programs that are only important
in the presence of specific microbial infections. Consistent with this
expectation, our data also support the notion that adaptation of
innate immune responses in primates primarily took place at the
level of ‘peripheral’ responses, namely, pathogen-specific immune
responses.
Species-specific immune responses
Among genes whose regulation was affected by stimulation with
LPS in only one species, we found an enrichment of genes
associated with response to viral infections. This observation might
Figure 4. An example of a functional network of genes that responded to stimulation with LPS exclusively in humans. Genes involved
in apoptosis and/or cancer pathways are highlighted.
doi:10.1371/journal.pgen.1001249.g004
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new defense mechanisms to fight viral infection, as viruses tend to
evolve faster than other microbes [33]. We also found that species-
specific immune responses are enriched with genes annotated to
have a role in apoptotic pathways. Apoptosis is a critical
component of successful immune response as infected cells have
to be efficiently removed without inciting an inflammatory
reaction [34]. Moreover, controlled cell death is used to restore
normal cell numbers following clonal expansion of antigen-specific
lymphocytes [34]. Consistent with our observation of rapid
evolution of the regulation of apoptotic pathways, coding regions
of apoptosis-related genes have previously been shown to be
rapidly evolving during primate evolution [7,35]. Put together,
these observations suggest that inter-species differences in
apoptosis-related immune responses may be adaptive. Although
the selective pressures underlying these adaptations are unclear,
these observations might help elucidate the basis for important
phenotypic differences between humans and non-human primates,
such as differences in susceptibility to cancer.
Indeed, cancer incidence in non-human primates is low
compared to that observed in humans, even when age is taken
into account [1,2,36–39]. The deregulation of apoptosis has been
extensively described as a hallmark of cancers [40]. Thus, while
our observation that the human-specific immune response to
stimulation with LPS is characterized by a significant enrichment
of cancer-related genes is not surprising (because the ‘cancer-
related’ and ‘apoptosis-related’ gene sets are not mutually
exclusive), it may provide a first step towards understanding the
mechanisms underlying the differences in cancer incidence
between humans and other primates. For example, we observed
that the pro-apoptotic gene CASP10 was strongly down regulated
early after stimulation with LPS, exclusively in humans (Figure
S7). Somatic mutations in CASP10, as well as reduced expression
levels of this gene, were found to be associated with a number of
different human cancers [41–44]. The observed inter-species
differences in the regulation of CASP10 following infection may
therefore be related to differences in the rates of cancer across
species. Detailed comparative studies of apoptosis-related regula-
tory mechanisms in model organisms will be necessary to fully
explore the possible connection between the predisposition to
cancer and inter-species differences in immune responses.
Inter-species differences in susceptibility to HIV/AIDS
Genes whose regulation was altered following stimulation with
LPS exclusively in humans were enriched with genes known to be
associated with susceptibility to infectious diseases or to immune-
related diseases. We did not observe such enrichment when we
considered the immune responses specific to chimpanzees or
rhesus macaques. Our observations make intuitive sense, as we
know more about the genes associated with diseases that affect
humans than those that affect the two non-human primate
species. In other words, it is reasonable to assume that we would
have found similar enrichments in chimpanzees and rhesus
m a c a q u e si fw ek n e wm o r ea b o u tt h eg e n e t i cb a s i so fi n f e c t i o u s
and immune-related diseases that primarily affect these two
species. Our observations thus underscore the link between
Figure 5. Co-expression regulatory networks. Heatmaps illustrating the correlations of expression profiles for genes responding to stimulation
with LPS exclusively in (A) humans, (B) chimpanzees, and (C) rhesus macaques are plotted. Blocks of genes with highly correlated expression profiles
correspond to regulatory modules determined by the MMC algorithm. We found 33, 17 and 32 modules in humans, chimpanzees and rhesus
macaques, respectively, with an average connectivity (|r|) higher than 0.5. In addition to the modules discussed in the text, regulatory modules that
merit particular attention include (D) module 13 in chimpanzees, which is significantly enriched for immune response genes (highlighted in yellow),
and (E) regulatory module 18 in rhesus macaques, which is significantly enriched for genes involved in immune-related pathways; in particular in MAP
kinase signaling pathways (highlighted in yellow), which control a range of cellular activities related to innate immune responses and are particularly
important in regulating cytokine gene expression levels and pathways related to programmed cell death [60].
doi:10.1371/journal.pgen.1001249.g005
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disease.
One interesting example is the enrichment of genes known to
interact with HIV among genes whose regulation was affected by
the stimulation with LPS exclusively in chimpanzee. This
observation is intriguing because, unlike humans and rhesus
macaques, a large number of studies propose that chimpanzees
only rarely develop AIDS following infection with HIV [45–47].
This notion has recently been challenged by Keele et al. [48], who
reported that wild chimpanzees naturally infected with SIVcpz do
develop hallmarks of AIDS. The apparently contradictory
observations in the literature might be explained by the fact that
Keele et al. used data collected from an eastern subspecies of
chimpanzees (Pan troglodytes schweinfurthii), whereas previous obser-
vations of increased protection from AIDS, were based on studies
with the western chimpanzee subspecies (Pan troglodytes verus), the
one used in our study. Differences in susceptibility to HIV between
sub-species of chimpanzees might be explained by the fact that Pan
troglodytes verus were physically separated from the two other sub-
species prior to systemic infection with the two recombinant
monkey viruses of SIVcpz.
Some examples of HIV-interacting gene that responded to
stimulation with LPS exclusively in chimpanzees include
ITGB2(CD18) and ITGAM(CD11b), which are the two members
of the complement receptor 3 (CR3) that have been shown to play
a key role in the infection of dendritic cells by C3-opsonized HIV
[49,50] and the viral transfer to CD4 T cells [50]. Interestingly,
these two genes were down-regulated after LPS stimulation,
exclusively in chimpanzee monocytes. Another example is the
APOBEC3F gene, which is one of the most potent inhibitors of
HIV replication [51] and was significantly up-regulated in
response to stimulation with LPS, only in chimpanzee monocytes.
The direction of regulatory change in these cases (namely, the
down regulation of a receptor that may be used by the HIV virus,
and the up-regulation of a known inhibitor of HIV replication), is
consistent with a theoretical mechanism of increased resistance of
chimpanzees (or at least Pan troglodytes verus) to progression of
AIDS. That said, future studies are now required to evaluate if the
down-regulation of CR3 and up-regulation of APOBEC3F are also
observed after infection with HIV (or SIVcpz).
Our observations may reflect an adaptation of the chimpanzee
immune system to infection with HIV/SIV or perhaps to other
retroviral infection(s). Previous studies of variation at the nucleotide
levelhavereportedthatgenesassociated withHIVinfection(suchas
CD45, APOBEC3G and APOBEC3H) evolved under positive
selection in primates [52], particularly after the divergence of
humans and chimpanzees [11]. Taken together, our data suggest
that regulatory changes occurring specifically in the chimpanzee
lineage might explain, at least in part, why chimpanzees tend not to
progress to AIDS following infection with HIV/SIV.
More generally, our observations may help to explain other
inter-species differences in susceptibility to infectious agents, such
as the increased resistance of chimpanzees to certain other viral
infections, including hepatitis B and C, and influenza A. Our
study, however, is only the first step in characterizing inter-species
differences in immune response, in particular because LPS is a
general stimulant. We expect future comparative studies in




This study was conducted according to the principles expressed
in the Declaration of Helsinki. An IRB approved consent form was
obtained from each human donor. Collection of the non-human
primate samples was perform at the Yerkes Primate Center, in a
manner that conformed to the animal subject regulatory standards
enforced by the Emory University Institutional Animal Care and
Use Committee (IACUC approved protocol #028-2009Y).
Sample collection
We measured gene expression levels in blood monocytes from
six humans, six chimpanzees and six rhesus macaques (three males
and three females from each species; see Table S13 for details on
all samples). Blood samples were collected in BD Vacutainer CPT
Cell Preparation Tube (BD, Franklin Lakes, NJ) and peripheral
blood mononuclear cells (PBMCs) were purified according to the
manufacturer’s instructions. Non-human primate blood samples
were collected at the Yerkes primate center and human samples
were obtained from Research Blood Components.
Monocyte purification and culturing
Blood monocytes from the three species were purified from
PBMCs using magnetic cell sorting technology (MACS technology
from Miltenyi Biotech). Specifically, monocytes from humans and
rhesus macaques were purified by positive selection with magnetic
CD14 MicroBeads (Miltenyi Biotech).This method did not work well
w i t ht h ec h i m p a n z e es a m p l e s( l e s st h a n3 %o fc h i m p a n z e eP B M C s
were isolated using cell sorting with a CD14 antibody). Instead,
monocytes from chimpanzees were purified by depletion of non-
monocyte cell types using the ‘‘Monocyte Isolation Kit II’’ (Miltenyi
Biotech). Regardless of the method used, the purity of the isolated
monocyte population was evaluated by flow cytometry. For the
human and rhesus macaque samples we used a fluorochrome-
Figure 6. Species-specific immune responses and disease
susceptibility. In both panels, the ‘all genes’ category (gray bar)
refers to the set of genes that were classified as expressed (based on
the array data) in at least one of the conditions (i.e., at any time point in
either the treated or untreated samples). (A) The proportions of genes
associated with infectious diseases or immune related disorders (y-axis)
among genes that responded to stimulation with LPS exclusively in
humans, chimpanzees and rhesus macaques (x-axis). (B) The proportion
of HIV-1 interacting genes (y-axis) among the subsets of genes that
responded to stimulation with LPS exclusively in each of the three
species (x-axis). The observed pattern is robust with respect to the
cutoffs used to classify genes as differentially expressed following the
treatment (Figure S5).
doi:10.1371/journal.pgen.1001249.g006
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coulter). For chimpanzees, we further confirmed the purity of the
monocyte population by also using two additional fluorochrome-
conjugated antibodies - against B-cells (CD20-PE; BD Bioscience)
and T-Cells (CD3-APC BD Bioscience). Regardless of species, only
samples with monocyte purity higher than 80% were used in
subsequent experiments (Figures S8 and S9). Finally, to further
increase the purity of the monocyte-enriched fraction (virtually to
100%), we performed an additional selection step based on the
unique capacity of monocytes/macrophages to strongly adhere to the
plastic of cell culture dishes. To do so, we cultured the cells overnight
(see below for details) and washed the cell culture wellsin the morning
to retain only adherent cells (i.e., monocytes).
Since we used different methods to purify monocytes in samples
from chimpanzees (negative selection) than in samples from
humans or rhesus macaques (positive selection), we also performed
a control experiment to empirically evaluate to what extent the
purification method used affects the ability of the purified cells to
respond to LPS stimulation. To do so, we collected whole blood
samples from three additional humans, from which we purified
monocytes using both a positive and a negative selection method.
We then performed the same LPS treatment experiment we
applied to the main samples from all three species (described
below), and compared differences in response to LPS treatment
between monocytes purified by positive selection and monocytes
purified by negative selection. As discussed in Text S1 and Figures
S15 and S16, we found that the method used to purify the
monocytes (negative or positive selection) has only a minimal effect
on the measured regulatory response to stimulation with LPS.
That said, to be conservative, we excluded from all analyses
presented in the manuscript the 192 genes identified as responding
to LPS treatment only in monocytes purified by either positive or
negative selection.
Monocyte culture and LPS stimulation
Monocytes were cultured in 24-well cell culture plates (Corning)
in serum free media (CTL’s test media) at a density of 1 million
cells per ml. We used a serum free media to minimize the
probability that the monocytes were non-specifically activated as a
result of the undefined nature of serum products (e.g., as a result of
a mitogenic serum batch). The cells were then stimulated with
1 ug/ml of LPS (Invivogen, Ultrapure LPS, E. coli 0111:B4) for 4,
12, and 24 hours. These time points were chosen based on
previous observations that the transcription kinetics of immune
response to infection can generally be characterized by early,
middle, and late phases of response, which can be effectively
captured at 4, 12 and 24 hours post infection [22]. All time course
experiments were started at the same time of day (,8am) to
prevent the introduction of variation due to differences in
circadian rhythm. Untreated cell cultures were kept alongside
the stimulated cultures and were harvested at the same time
intervals (4, 12, and 24 hours post stimulation).
RNA extraction and amplification
Total RNA from each cell culture was extracted using RNeasy
columns (Qiagen, Valencia, CA). For all samples, RNA quantity
was evaluated spectrophotometrically, and the quality was assessed
with the Agilent 2100 bioanalyzer (Agilent Technologies Inc, Palo
Alto, CA). Only samples with no evidence for RNA degradation
(RNA integrity number .8.5) were retained for further experi-
ments. To evaluate the activation of monocytes after stimulation,
we used quantitative PCR to test for an over-expression of Tumor-
necrosis Factor (TNF-a), Interleukine-6 (IL-6) and IL1-b. inflam-
matory cytokines that are known to be induced following the
activation of TLRs (primer sequences and PCR conditions can be
found in Table S14). Only samples for which we observed a
significant induction of these cytokines were used in downstream
experiments. Once we confirmed that monocytes from all three
species responded to the treatment, we performed linear
amplifications of the total RNA samples by using in-vitro
transcription. Specifically, 400 ng of high-quality total RNA were
amplified using the MessageAmp II kit (Ambion). Unlike
exponential RNA amplification methods, aRNA amplification
has been shown to maintain the relative representation of the
starting mRNA population [53,54] (Figure S10).
Multi-species microarray
To compare genome-wide gene expression levels between
humans, chimpanzees, and rhesus macaques, we hybridized the
RNA samples to the multi-species microarray described by
Blekhman et al. [30]. This array contains orthologous probes
from the three species, thus allowing a comparison of gene
expression levels between species without the confounding effects
of sequence mismatches on hybridization intensities [30]. The
microarray contains probes for 18,109 genes (see Blekhman et al.
[30] for a detailed description of the multi-species array). The
labeling of the amplified RNA samples and subsequent hybrid-
ization to the microarray were performed by Nimblegen. For each
individual we hybridized one non-stimulated and one stimulated
sample at each of the three time points (4 hours, 12 hours and
24 hours). The total number of arrays analyzed was therefore 108
(=3 species 66 individuals 66 arrays per individual). Quality
control, background correction and normalization of the expres-
sion data were performed as previously described [30] (Figure S11
and S12).
Statistical analysis
All the statistical analyses detailed in this and the following
sections were performed using the R statistical environment
(http://www.r-project.org).
Identifying genes differentially expressed between
species. We analyzed data from the 17,231 genes (95% of the
genes on the array) that were assayed by at least three orthologous
probes across all species. To identify differentially expressed genes
between the three species, across time-points and following the
treatment, we modeled the expression levels of each gene
independently by using a linear mixed-effects model similar to
the one described in Blekhman et al. [30]. Specifically, for each of
the 17,231 genes, if ysroi denotes the normalized log2 intensity
expression value for individual i (i=1,..6), from species s
(s=human, chimpanzee or rhesus macaque), measured at probe




Here, ms is a species-specific fixed-effect (representing changes in
expression levels across the three species), pro is a fixed-effect
representing the probe effect for each individual probe within a
probe-set and the composition effect of species-specific orthologous
probes, and ksro is a fixed-effect representing the attenuation of
hybridization intensities due to sequence mismatches between
species of RNA and a species-specific derived probe, which are
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reference [30] for more details). The term csi represents a
random-effect for individual i from species s; this effect is assumed
to follow a Normal distribution with mean 0 and variance s2
rand.
To determine whether a gene was differentially expressed between
species, we assessed how well model (1) fitted the data under the
following parameterizations of ms:
M0 : mH~mC~mR
M1 : mH=mC=mR
In the null model (M0) the gene’s expression level is assumed to
be constant across the three species, while in the alternative model
(M1) the expression level is allowed to differ between species. We
maximized the likelihood under these two parameterizations using
an iterated least-squares approach and compared the fit of the
models by calculating the likelihood-ratio test statistic. We
calculated p-values based on a x
2 distribution with two degrees
of freedom, and corrected for multiple testing using the FDR
approach of Benjamini and Hochberg[55].
Identifying genes whose expression level was altered
following stimulation with LPS treatment. Due to the
paired nature of the study design (untreated and treated cells
from the same individual are compared), parameterizations of an
extended version of model (1) are difficult to interpret. Instead, we
first regressed out probe effects and then used a linear model
framework to identify genes whose expression levels have changed
following the treatment. To regress out probe effects, we
considered data from each time point separately. For each gene,
if ysroit denotes the normalized log2 intensity expression value for
individual i (i=1,..6), from species s (s=human, chimpanzee or
rhesus macaque), from class t (t=non-stimulated or stimulated)





In the above, ms, pro, and ksro are defined as in the previous
section. However, we have added two additional terms to the
model: at (a treatment effect) and bst (a treatment-by-species
interaction). Further, the parameterization of the random effect
has been modified to reflect the incorporation of the treatment
effect, such that csit*N(0,s2
rand). We used a maximum likelihood
approach to estimate the parameters in this model, and
subsequently calculated a corrected measure of expression, ^ y ysit
for each individual i from each species s and for the two classes
t as: ^ y ysit~^ m msz^ c citz^ a atz^ b bst (^ m ms denotes the maximum likelihood
estimate of ms et cetera). We analyzed these corrected measures of
expression levels further using gene-wise models. Specifically, for
each species separately, if yit denotes the corrected gene expression
level in individual i undergoing treatment t at the four hour time-
point, we fitted the following two models:
H0 : yit~mzcizeit
H1 : yit~mzcizbtzeit
Here, m corresponds to an intercept, c corresponds to an
individual effect (shared across treatments), b corresponds to a
treatment effect and e is assumed to follow a normal distribution
with mean 0 and variance s2. We tested whether there was
significant evidence of a difference in expression levels between the
treated and un-treated samples by comparing the fit of these
models using a likelihood-ratio test statistic. We calculated p-values
based on a x
2 distribution with one degree of freedom.
Ultimately, our goal was to identify inter-species differences in
the regulatory response to stimulation with LPS. To minimize the
number of falsely identified differences across species we applied
two statistical cutoffs for classifying genes as responding to the
treatment. Specifically, as a first step, at each time point, using
data from the human and rhesus macaque samples, we initially
classified genes as differently expressed following the treatment
using an FDR cutoff ,0.001, also requiring that the effect size of
the treatment was equal or larger than |0.3| (log2 scale). For data
from the chimpanzee samples, we chose to use different initial
cutoffs (an FDR,0.1, and an absolute effect size cutoff of 0.1), as
the effect sizes for the regulatory response to the treatment were
overall lower (importantly, however, the overlap in lists of
responding genes across species is high regardless of the specific
cutoff used; Figure S13, Table S15). We then assumed that,
conditional on observing a treatment effect with high statistical
confidence in one species, a treatment effect likely occurred in
other species as well. To classify such secondary observations we
used a relaxed cutoff of P,0.05. This approach is therefore
conservative with respect to identifying differences in immune
response across species. While the specific numbers reported in the
paper are based on arbitrarily chosen cutoffs, the qualitative
conclusions we discuss are robust with respect to the specific choice
of cutoffs within a considerable range (Table S16 and Figure S5).
Gene ontology and pathway enrichment analysis
We used GeneTrail (http://genetrail.bioinf.uni-sb.de) [56] to
test for enrichment of functional annotations among different
classes of genes (as detailed in the results). In all tests, we used a
background set of 13,244 genes, which were classified as expressed
(using an absolute log2 intensity cutoff of 7.5; Figure S14) in at least
one species at one condition; that is, any of the time points for the
non-stimulated or stimulated samples. The tests were performed
using all GO categories and KEGG pathways. We calculated p-
values using a Hyper-geometric distribution, and used the
approach of Benjamini and Hochberg [55] to control the false
discovery rate.
Enrichment of transcription factor binding sites
We applied the promoter analysis algorithm PRIMA imple-
mented in the EXPANDER package [57]. Given a target set and a
background set of genes, PRIMA identifies transcription factor
binding motifs that are significantly more prevalent in the
promoter of the target set than in the background set. As
background we used all the genes in the array that had at least 3
homologous probes across species and that were expressed in at
least one species in one of the six conditions (i.e., any of the three
time-point in either treated or non-treated samples).
Network analysis
We looked for known functional associations between the 335
human-specific LPS response genes using the STRING database
(http://string.embl.de/). STRING is a database of both known
and predicted protein-protein interactions, which includes direct
(physical) and indirect (functional) associations derived from
numerous sources, including experimental repositories, computa-
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selected all interactions/associations available for a given node
with a combined score greater than 0.7. The scores given in the
STRING database define the confidence limit for each described
interaction/association. A combined score of 0.7 is recommended
as the high stringency criterion by the database authors.
In turn, to identify modules of co-expressed genes, we used the
Modulated Modularity Clustering (MMC) algorithm, which seeks
community structure in graphical data; that is, a graph of genes
connected by edges whose weights reflect the degree to which their
transcriptional profiles are correlated (see reference [58] for a
detailed description of the method). Co-expression modules were
defined using the probe-corrected expression estimates for the set
of 335, 273 and 393 genes whose expression levels were altered
following the treatment exclusively in humans, chimpanzees and
rhesus macaques, respectively.
Analysis of genes associated with disease
Genes previously reported to be associated with immune
disorders and/or susceptibility to any infectious disease were
identified using the Genetic Association Database (http://
geneticassociationdb.nih.gov/). We downloaded the full GAD
dataset on Nov 9, 2009, and parsed the all.xls table, which
contains gene-disease associations. We labeled genes as immune-
related if they had been associated with diseases for which the
‘disease class’ field in the GAD database was defined as ‘Immune’
or ‘‘Infectious diseases’’. The list of host genes known to interact
with HIV-1 proteins was retrieved from the HIV-1 Human
Protein Interaction Database, which catalogues over 1,400 human
proteins reported in the scientific literature to participate in HIV-1
to human protein interactions [59].
Supporting Information
Figure S1 Illustrative representation of the microarray hybrid-
ization study design. From each individual we hybridized one non-
stimulated (NS) and one LPS stimulated (LPS) sample at each of
three time points (4 hours, 12 hours and 24 hours) yielding a total
of 6 arrays per individual. The total number of arrays analyzed
was therefore 108 (=3 species 66 individuals 66 arrays per
individual).
Found at: doi:10.1371/journal.pgen.1001249.s001 (0.07 MB
DOC)
Figure S2 Representative examples of the induction (y-axis) of
TNF-a, IL-6 and IL-1b after stimulation of monocytes with LPS,
as measured by real-time PCR in A) humans, B) chimpanzees and
C) rhesus macaques, at 4, 12, or 24 hours post treatment (x-axis).
Found at: doi:10.1371/journal.pgen.1001249.s002 (0.23 MB
DOC)
Figure S3 Pairwise comparisons of differences in gene expres-
sion levels following the treatment between (a) humans and rhesus
macaques, (b) humans and chimpanzees, and (c) rhesus macaques
and chimpanzees. Data for genes that were classified as differently
expressed following the treatment in both species is plotted in red.
As shown, the vast majority of genes responded to the treatment in
the same direction, regardless of species.
Found at: doi:10.1371/journal.pgen.1001249.s003 (0.62 MB
DOC)
Figure S4 Venn-diagrams showing the number of genes that
responded to the treatments in humans, chimpanzees and rhesus
macaques 4- 12- and 24-hours following the treatment.
Found at: doi:10.1371/journal.pgen.1001249.s004 (0.15 MB
DOC)
Figure S5 The proportion of HIV-1 interacting genes (y-axis)
among the subsets of genes that responded to stimulation with LPS
exclusively in each of the three species. In contrast to the results
reported in the main paper, here we used the same cutoffs in all
species (i.e., FDR,0.01 and 0.1 absolute fold-change cutoff) to
classify genes as differently expressed following the treatment. ‘‘all
genes’’ (gray bar) refer to the set of genes that were expressed in at
least one of the conditions (i.e., at any time point for either the LPS
treated or untreated samples). As can be seen, the pattern we
reported in the main paper is robust with respect to the particular
choice of the statistical cutoff. We note that the enrichment of
HIV-1 interacting genes among chimpanzee-specific responses is
also significant when compared to the proportions of HIV-1
interacting genes observed among human- and rhesus macaques-
specific immune responses (Chi2 test; P,0.002).
Found at: doi:10.1371/journal.pgen.1001249.s005 (0.08 MB
DOC)
Figure S6 Reduction of inter-species variation in gene expres-
sion levels following stimulation with LPS for a number of key
transcription factors involved in the regulation of TLR4-
dependent pathways. The genes presented in the figure are all
differently expressed between species before the treatment
(FDR,0.05), yet, following infection (mostly 4 hours after
infection) their expression converged to practically the same level,
regardless of species (P.0.05). The broken lines are for illustration
purposes only.
Found at: doi:10.1371/journal.pgen.1001249.s006 (0.13 MB
DOC)
Figure S7 CASP10 LPS responses in humans, chimpanzees and
rhesus-macaques at different time-points post stimulation. The
solid lines are for illustration purposes only.
Found at: doi:10.1371/journal.pgen.1001249.s007 (0.06 MB
DOC)
Figure S8 Representative plots of flow-cytometry analyses on
total PBMC (left panels) and CD14+ cell fractions (right panels)
purified by magnetic cells sorting for A) human and B) rhesus
macaque samples.
Found at: doi:10.1371/journal.pgen.1001249.s008 (0.29 MB
DOC)
Figure S9 Plots of flow-cytometry analyses of the different cell
fractions in a representative chimpanzee sample, obtained after
depletion of non-monocyte populations using MACS technology.
Total PMBCs (A), depleted fraction (B) or monocyte enriched
fraction (C) were stained with antibodies against CD20 - a marker
of B-cells and CD3 - a marker of T-cells (left panels), and CD14 - a
marker of monocytes (right panels).
Found at: doi:10.1371/journal.pgen.1001249.s009 (0.60 MB
DOC)
Figure S10 Representative examples of the minimal variance
introduced by RNA amplification. The fold induction in
expression levels (y-axis) observed 4 hours after stimulation with
LPS for three genes (x-axis) is compared between amplified and
non-amplified RNA samples.
Found at: doi:10.1371/journal.pgen.1001249.s010 (0.08 MB
DOC)
Figure S11 Boxplots of post normalization gene expression
values.
Found at: doi:10.1371/journal.pgen.1001249.s011 (0.21 MB
DOC)
Figure S12 Principal component analysis (PCA) of post
normalization array data. As expected based on the known
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separates humans and chimpanzees from rhesus macaques and the
second principal component separates humans from chimpanzees.
Found at: doi:10.1371/journal.pgen.1001249.s012 (0.09 MB
DOC)
Figure S13 Overlap between species (y-axis) in the ranks of
genes showing the strongest responses to LPS-stimulation (x-axis).
Found at: doi:10.1371/journal.pgen.1001249.s013 (0.16 MB
DOC)
Figure S14 Cutoff defined to exclude genes that are not
expressed. Average intensity (y-axis) is plotted against estimates
of the between-individual variance (x-axis). The red line is the
cutoff below which genes are likely not to be expressed; hence we
excluded these genes from the enrichment analyses.
Found at: doi:10.1371/journal.pgen.1001249.s014 (0.06 MB
DOC)
Figure S15 Impact of the monocytes’ purification method on
the measured immune responses to LPS stimulation. Correlation
between the LPS responses of monocytes purified by positive
selection and monocytes purified by negative selection, at (A)
4 hours, (B) 12 hours, and (C) 24 hours after LPS treatment. (D)
Venn-diagram showing the number of genes whose expression
levels were altered following stimulation with LPS in monocytes
purified by positive selection (yellow) and monocytes purified by
negative selection (green).
Found at: doi:10.1371/journal.pgen.1001249.s015 (0.15 MB
DOC)
Figure S16 Lack of association between genes that responded to
LPS only in monocytes purified by negative section and genes
classified as responding to LPS treatment exclusively in chimpan-
zees. In the y-axis we report the P-value for the enrichment (using
a re-sampling procedure) of chimpanzee-specific response genes
among genes classified as responding to LPS only in monocytes
purified by negative section, using different cutoffs (x-axis). Blue
dots refer to a two-cutoff approach as we did in our manuscript.
Specifically, condition on observing a gene differently expressed in
one of the purification methods at a given cutoff (in the x-axis) we
consider that that gene was also differently expressed after LPS
treatment in the other purification method at a nominal P-
value=0.05.
Found at: doi:10.1371/journal.pgen.1001249.s016 (0.07 MB
DOC)
Table S1 List of genes analysed in the study.
Found at: doi:10.1371/journal.pgen.1001249.s017 (10.08 MB
XLS)
Table S2 KEGG pathways and Gene Ontology (GO) enrich-
ment analyzes for the set of genes that responded to LPS in all
three species. Only the top 100 GO enrichment terms are shown.
Found at: doi:10.1371/journal.pgen.1001249.s018 (0.16 MB
DOC)
Table S3 Results of transcription factor binding sites enrichment
analyzes using the promoter sequences of the set of genes that
responded to LPS in all three species.
Found at: doi:10.1371/journal.pgen.1001249.s019 (0.08 MB
DOC)
Table S4 List of genes that responded to the LPS treatment in
our experiment and that, following the findings from Amit et al.,
were classified as being part of the universal TLR response, the
immune responses specific to bacterial infections, or the immune
responses specific to viral infections. As expected, genes classified
as part of the universal response are highly enriched for genes
annotated as being involved in the toll-like receptor signaling
pathway (FDR,10-9; no such enrichment is observed among
bacterial- or viral-specific response genes), whereas genes classified
as primarily involved in immune responses to viral infections are
markedly enriched for genes classified as involved in ‘‘response to
viruses’’ (GO term 0009615; FDR=0.005), and virus-host
interaction (GO term 0019048; FDR=0.04).
Found at: doi:10.1371/journal.pgen.1001249.s020 (0.29 MB
DOC)
Table S5 KEGG pathways enrichment analyzes for the 335
genes that responded to LPS only in humans.
Found at: doi:10.1371/journal.pgen.1001249.s021 (0.05 MB
DOC)
Table S6 KEGG pathways enrichment analyzes for the 273
genes that responded to LPS only in chimpanzees.
Found at: doi:10.1371/journal.pgen.1001249.s022 (0.03 MB
DOC)
Table S7 KEGG pathways enrichment analyzes for the 393
genes that responded to LPS only in rhesus macaques.
Found at: doi:10.1371/journal.pgen.1001249.s023 (0.03 MB
DOC)
Table S8 Functional interaction scores between the set of 335
genes that respond to LPS exclusively in humans. Only
interactions with a score higher than 0.4 (the default cutoff in
STRING) are shown.
Found at: doi:10.1371/journal.pgen.1001249.s024 (0.17 MB
DOC)
Table S9 Sources of information used to support evidence of a
functional interaction between genes that responded to LPS only
in humans.
Found at: doi:10.1371/journal.pgen.1001249.s025 (0.13 MB
DOC)
Table S10 Co-expression modules and GO enrichement
analyses for Human-specific response genes.
Found at: doi:10.1371/journal.pgen.1001249.s026 (0.09 MB
XLS)
Table S11 Co-expression modules and GO enrichement
analyses for Chimpanzee-specific response genes.
Found at: doi:10.1371/journal.pgen.1001249.s027 (0.08 MB
XLS)
Table S12 Co-expression modules and GO enrichement
analyses for Rhesus-specific response genes.
Found at: doi:10.1371/journal.pgen.1001249.s028 (0.10 MB
XLS)
Table S13 Details on the samples used in this study
Found at: doi:10.1371/journal.pgen.1001249.s029 (0.04 MB
DOC)
Table S14 Primer sequences and PCR conditions for the genes
used to validate the immune response to the treatment.
Found at: doi:10.1371/journal.pgen.1001249.s030 (0.03 MB
DOC)
Table S15 Overlap between the top-ranked genes that respond-
ed to the treatment in the different species. We considered the N
genes (100, 200, 300, 400, 500, or 1000) showing the largest
absolute changes in expression levels following the treatment for
each species, and then compared the sets of top ranked genes
among species. We report the fold-enrichment for overlap in the
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number of expressed genes at that time point in each species).
Found at: doi:10.1371/journal.pgen.1001249.s031 (0.03 MB
DOC)
Table S16 Consistent enrichment of apoptosis and cancer
related genes among human-specific response genes regardless of
the cutoffs (within a considerable range) used to define differently
expressed genes.
Found at: doi:10.1371/journal.pgen.1001249.s032 (0.03 MB
DOC)
Text S1 Results from a control experiment testing for possible
biases due to the choice of monocyte purification approach.
Found at: doi:10.1371/journal.pgen.1001249.s033 (0.04 MB
DOC)
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